Detailed Narrative
Robust Q1 FY26 Financial Performance
Windlas Biotech reported a strong Q1 FY26, marking its tenth consecutive quarter of record revenue performance. Revenue grew 20% Y-o-Y to INR 210 crores, with EBITDA increasing 27% Y-o-Y to INR 27 crores and PAT rising 31% Y-o-Y to INR 18 crores. The company's EPS for the quarter stood at INR 8.4, reflecting a 30% increase over the previous year.
Significant Margin Expansion
The company demonstrated notable margin improvement during the quarter. Gross margin expanded by 71 basis points Y-o-Y to reach 38.3%, while the EBITDA margin improved by 70 basis points, settling at 12.6%. This expansion is attributed to ongoing operational efficiencies, though specific details on cost absorption from new facilities were not explicitly provided.
Broad-Based Growth Across All Verticals
Growth was broad-based, with all three business verticals contributing positively. The Generic Formulations CDMO vertical achieved a 17.8% Y-o-Y growth, contributing INR 160 crores in revenue. The Trade Generics and Institutional vertical grew by 25.2% Y-o-Y to INR 44 crores, and the Exports vertical recorded a substantial 45.4% Y-o-Y growth, reaching INR 6 crores.
Strategic Capacity Expansion and Future Revenue Potential
Windlas is actively pursuing capacity expansion, with the recently acquired Plant 6 undergoing refurbishment, for which INR 40-50 crores CapEx is planned. Management expects mechanical refurbishment and validation to be completed within 2-3 quarters. Once Plant 6 is fully capitalized, the combined capacity of existing and new plants is projected to deliver INR 1,100 crores in revenue at peak utilization, with injectables contributing approximately INR 100 crores.
Benefits from Schedule M and Trade Generics Market Dynamics
The company anticipates benefiting from stricter Schedule M regulations, as increased quality expectations favor organized players with robust infrastructure and systems. In the Trade Generics segment, Windlas aims to expand its distribution network to an aspirational 5,000-6,000 stockists, focusing on product depth and strengthening presence in underserved regions. Management believes the vast Indian market, particularly in rural areas, offers significant growth opportunities despite increasing competitive intensity.
Capital Allocation and Shareholder Value Creation
Windlas Biotech remains committed to shareholder value creation, having paid a dividend of INR 12.2 crores (INR 5.8 per share) for FY25, consistent with its policy of distributing around 20% of its profit. While the company has accumulated cash, it is cautiously exploring M&A opportunities for inorganic growth, emphasizing a judicious and thoughtful approach to capital deployment for strategic dosage form expansion.